// App-Quantinova.ai

1348 : Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials

Researchers

Presenter

  • Maxime Dougados

Principal Investigators

  • Eduardo Mysler

  • Mark Genovese

  • Cassandra Kinch

  • Kenneth Kwok

  • Tatjana Lukic

  • Tanya Girard

  • Pierre-Alexandre Landry

  • Ronald van Vollenhoven

Medical Centers

  • Laval University, Quebec, Quebec, Canada.

  • Bichat Hospital, Paris, France

  • Organizacion Medica de Investigacion, Buenos Aires, Argentina

  • Pfizer Canada Inc, Kirkland, QC, Canada

  • Pfizer Inc, New York, NY

  • Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

Locations

  • Canada

  • France

  • Argentina

  • United States

  • Netherlands

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Albumin/creatinine

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • III

Study Id's

  • NCT00847613

  • NCT00856544

  • NCT00853385

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved